Skip to Main Content

National Coverage Analysis (NCA) Tracking Sheet for Lung Cancer Screening with Low Dose Computed Tomography (CAG-00439N)

Effective January 1, 2009, CMS is allowed to add coverage of "additional preventive services" if certain statutory requirements are met. Per Section 1861(ddd) of the Social Security Act and implementing regulations at 42 CFR 410.64, CMS may cover "additional preventive services", if it determines through the national coverage determinations (NCD) process that the service is recommended with a grade A (strongly recommends) or grade B (recommends) rating by the United States Preventive Services Task Force (USPSTF) and that it also meets certain other requirements.

CMS has accepted two formal complete requests to initiate a NCA on Lung Cancer Screening with Low Dose Computed Tomography (LDCT), which is recommended with a grade B by the USPSTF for certain persons at high risk for lung cancer based on age and smoking history. The scope of our review is limited to LDCT Screening for lung cancer. We are particularly interested in evidence to inform the identification of patients eligible for screening; the appropriate frequency and duration of screening; facility and provider characteristics that predict benefit or harm; precise criteria for test positivity and the impact of false positive results and followup tests or treatments. We are also soliciting input on the influence of these factors on patient education and informed consent in Medicare beneficiaries including the elderly and younger disabled populations and persons receiving dialysis treatment for end stage renal disease; and on the integration of smoking cessation interventions for current smokers.

On April 30, 2014, we are convening a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting to review the available evidence on this topic.

Additional Preventive Services
Requestor Name(s)Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center; Laurie Fenton Ambrose, President & CEO, Lung Cancer Alliance
Requestor Letter(s)View Letter View Letter
Formal Request Accepted and Review Initiated02/10/2014
Expected NCA Completion Date02/08/2015
Public Comment Period02/10/2014 - 03/12/2014
Proposed Decision Memo Due Date11/10/2014
Comments for this NCA:View Public Comments
Lead Analyst(s)
Lead Medical Officer(s)
  • Joseph Chin, MD, MS

February 10, 2014

CMS initiates this national coverage analysis on Lung Cancer Screening with LDCT. The initial 30-day public comment period begins with this posting date, and ends after 30 calendar days.

CMS considers all public comments, and is particularly interested in comments that include published clinical studies and other scientific information that provides evidence for improvement in short and long term outcomes related to this screening service.

Instructions on submitting public comments can be found at http://www.cms.gov/Medicare/Coverage/InfoExchange/publiccomments.html. You can also submit a public comment by clicking on the highlighted word comment in the title bar at the top of this page. We strongly urge that all public comments be submitted through this website. Please do not submit personal health information in public comments. Comments with personal health information may not be posted to the website.

34